Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes

Simon Heller, João Filipe Raposo, Santiago Tofé, Wasim Hanif, Zbynek Schroner, Su Down, Thomas Blevins

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)
17 Downloads (Pure)

Abstract

Despite increases in the availability and effectiveness of other therapies, insulin remains an essential treatment for approximately 30 million people with type 2 diabetes worldwide. The development of biosimilars has created the potential for significant health care cost savings and may lead to greater access to basal insulin for vast populations. In this review, we discuss evidence demonstrating equipoise between basal insulin biosimilars and the patented analogs they may replace.

Original languageEnglish
Pages (from-to)154-162
Number of pages9
JournalClinical Diabetes
Volume41
Issue number2
DOIs
Publication statusPublished - Mar 2023

Fingerprint

Dive into the research topics of 'Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes'. Together they form a unique fingerprint.

Cite this